| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
IPCA Laboratories Limited (NSE: IPCALAB)
IPCALAB Technical Analysis
5
| As on 24th Apr 2024 IPCALAB SHARE Price closed @ 1347.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 997.02 & Strong Buy for SHORT-TERM with Stoploss of 1224.11 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IPCALABSHARE Price
| Open | 1322.15 | Change | Price | % |
| High | 1356.30 | 1 Day | 23.30 | 1.76 |
| Low | 1319.25 | 1 Week | 5.75 | 0.43 |
| Close | 1347.25 | 1 Month | 151.20 | 12.64 |
| Volume | 564608 | 1 Year | 520.75 | 63.01 |
| 52 Week High 1076.80 | 52 Week Low 675.00 | ||||
| IPCALAB CURRENT MONTH FUTURE | |||
| Close | 1346.00 | ||
| Contracts Traded | 1137500 | ||
| Open Intrest | 1197950 | ||
| Change In O.I | -23.79 % | ||
| Lot Size | 650 | ||
| IPCALAB CURRENT MONTH OPTION | |
| Most Active Call | 1400.00 |
| Most Active put | 1300.00 |
| Highest O.I Buildup Call | 1400.00 |
| Highest O.I Buildup Put | 1200.00 |
| Expiry Date | 2024-04-25 |
| IPCALAB ALL MONTHS OPTIONS | |||
| For All IPCALAB Options Click Here | |||
NSE INDIA Most Active Stocks
| IDEA | 13.10 | -9.03% |
| SAIL | 164.65 | 8.14% |
| YESBANK | 25.45 | -0.78% |
| TATASTEEL | 165.55 | 2.73% |
| IRFC | 149.00 | 0.85% |
| SOUTHBANK | 29.10 | 1.04% |
| MRPL | 248.70 | 10.75% |
| SUZLON | 41.80 | -0.12% |
| BEL | 236.50 | 0.92% |
| RAMASTEEL | 14.00 | 2.56% |
NSE INDIA Top Gainers Stocks
| ROML | 63.05 | 19.98% |
| COMPUSOFT | 35.20 | 19.93% |
| SHRADHA | 78.55 | 19.83% |
| STEELCITY | 102.95 | 19.78% |
| WEIZMANIND | 142.25 | 19.59% |
| TEMBO | 240.90 | 18.61% |
| CHENNPETRO | 1075.00 | 15.82% |
| YUKEN | 1180.65 | 13.81% |
| ORIENTCEM | 230.50 | 12.85% |
| AEGISCHEM | 604.50 | 12.41% |
NSE INDIA Top Losers Stocks
| IPCALAB Daily Charts |
IPCALAB Intraday Charts |
Whats New @ Bazaartrend |
IPCALAB Free Analysis |
|
|
IPCALAB Important Levels Intraday
| RESISTANCE | 1418.65 |
| RESISTANCE | 1395.75 |
| RESISTANCE | 1381.60 |
| RESISTANCE | 1367.44 |
| SUPPORT | 1327.06 |
| SUPPORT | 1312.90 |
| SUPPORT | 1298.75 |
| SUPPORT | 1275.85 |
IPCALAB Target April 2024
| 4th UP Target | 1584.04 |
| 3rd UP Target | 1458.65 |
| 2nd UP Target | 1381.14 |
| 1st UP Target | 1303.63 |
| 1st DOWN Target | 1082.47 |
| 2nd DOWN Target | 1004.96 |
| 3rd DOWN Target | 927.45 |
| 4th DOWN Target | 802.06 |
IPCALAB Weekly Target
| 4th UP Target | 1468.89 |
| 3rd UP Target | 1426.90 |
| 2nd UP Target | 1400.94 |
| 1st UP Target | 1374.98 |
| 1st DOWN Target | 1300.92 |
| 2nd DOWN Target | 1274.96 |
| 3rd DOWN Target | 1249.00 |
| 4th DOWN Target | 1207.01 |
IPCALAB Target2024
| 4th UP Target | 2061.33 |
| 3rd UP Target | 1757.24 |
| 2nd UP Target | 1569.28 |
| 1st UP Target | 1381.32 |
| 1st DOWN Target | 844.98 |
| 2nd DOWN Target | 657.02 |
| 3rd DOWN Target | 469.06 |
| 4th DOWN Target | 164.97 |
IPCA Laboratories Limited ( NSE INDIA Symbol : IPCALAB )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IPCALAB Synopsis Technicals View
| 50 Day EMA |
Close is Above EMA 50 (Short Term) |
Bullish | |
| 100 Day EMA | Close is Above EMA 100 (Mid Term) | Bullish | |
| 200 Day EMA | Close is Above EMA 200 (Long Term) | Bullish | |
| MACD (12 26 9) | MACD Line is Less Then SIGNAL Line | Bearish | |
| RSI (14) | RSI is 44.05 | Sideways | |
| MFI (14) | MFI is 38.99 | Sideways | |
| CCI (20) | CCI is Below -100 | Over Sold | |
| WILLIAM %R (14) | William %R is Below -80 | Over Sold | |
| ADX (14) | ADX is Above 20 & +DI is Above -DI | Up Trend | |
| PSAR | Stoploss For Short Sell | 1500.45 | |
| 10 Day Avg Volume | Traded -25.56 % Less then 10 Day Average Volume | ||
IPCALAB Other Details
| Segment | EQ | |
| Market Capital | 278177841152.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
IPCALAB Address
 |
||
IPCALAB Latest News
IPCALAB Business Profile
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. It also provides generic and branded formulations in the therapeutic segments, including cardiology, gastroenterology, dermatology, rheumatology, urology, ophthalmology, infectious disease, immunosuppressant, probiotics, respiratory, allergy, nutraceuticals, anti-neoplastic, malarial, neurology, psychiatry, orthopedics, helminthics, fever, hematology, hepatoprotective, diabetology, anti-epileptic, emollients/protectives, NSAIDs, rheumatology, anti-arthritic, and neuropathic pain, as well as products in various dosage forms comprising oral solids, powders for suspension, and liquid and dry injections. The company exports its products to approximately 100 countries worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India. Address: 125, Kandivli Industrial Estate, Mumbai, India, 400067
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service